Throughout this site, I've talked about fat tissue as metabolically active — producing signals, not just storing energy. This post is about the two hormones most responsible for that signaling: leptin and adiponectin. Understanding them properly clears up a genuine, common misconception, and it gives me a chance to introduce a marker I think deserves far more attention than it usually gets.
Fat tissue as an endocrine organ
I touched on this in the visceral fat post earlier in this series: fat isn't a passive storage depot. It's active tissue that produces hormones, and two of the most important are leptin and adiponectin. Both are made by fat cells, both circulate throughout the body, and both play a direct role in regulating appetite, energy use, and insulin sensitivity. But they behave in ways that surprise a lot of patients when I explain them.
Leptin: the misconception worth correcting
Leptin's job is to signal satiety — it tells your brain how much energy is stored and helps regulate appetite accordingly. Given that role, you'd reasonably assume that in obesity, leptin would be low, since appetite regulation is clearly not working the way it should.
The opposite is true. In obesity, leptin is usually elevated, often substantially. More fat tissue means more leptin production. The actual problem isn't a leptin deficiency — it's leptin resistance, a state where the brain stops responding appropriately to the leptin signal it's already receiving, similar in concept to insulin resistance, which I've written about elsewhere on this site. The signal is there. The response to it has broken down.
This distinction matters clinically. It means the goal was never "increase leptin" — a patient with obesity typically doesn't need more leptin, they need their brain to start listening to the leptin they already have. That reframes the target: reducing visceral fat and improving the underlying metabolic and inflammatory environment tends to improve leptin sensitivity, rather than simply raising or lowering the hormone itself.
Adiponectin: the opposite pattern
Adiponectin behaves almost in reverse. Rather than rising with fat mass, it tends to fall as visceral fat and insulin resistance increase. Higher adiponectin — particularly a specific, more active form of it — is associated with better insulin sensitivity, more efficient fatty-acid metabolism, and a less inflammatory pattern of fat tissue overall.
This connects directly to the inflammation posts earlier in this series. Adiponectin isn't just a metabolic marker — it has real anti-inflammatory signaling properties, and its decline in states of visceral obesity is part of why visceral fat accumulation and chronic inflammation tend to move together rather than independently.
A useful way to think about the target
Putting these two together gives a cleaner picture than looking at either alone: the healthier direction isn't simply "more of one hormone, less of the other" in isolation — it's a pattern. Lower leptin resulting from reduced visceral fat and restored leptin sensitivity, combined with higher adiponectin reflecting healthier, less inflamed adipose tissue, together describe a genuinely improving metabolic state.
Some researchers look at this as a ratio — leptin relative to adiponectin — rather than either number alone, since the ratio captures the shift between dysfunctional and healthier adipose tissue more clearly than a single marker does. I find that framing useful, and it's consistent with something I've said throughout this site in different forms: a single number rarely tells the whole story, but the right combination of numbers, read together, often does.
Why this matters beyond the lab report
None of this is abstract biochemistry disconnected from what patients actually experience. Leptin resistance is part of why appetite regulation can feel so stubbornly resistant to willpower alone — a point I made in an earlier post about what 25 years of surgery taught me about willpower. And declining adiponectin as visceral fat accumulates is part of the same insulin resistance and inflammatory cascade that runs through nearly everything else I've written about on this site.
In the next post, I'll get into how specific treatments — GLP-1 therapy, and some more exploratory peptide research — actually affect these two hormones, and importantly, how differently established that evidence is depending on which treatment we're talking about.
Curious what your own adipose signaling markers actually look like?
No spam. Occasional new posts and updates from The Center for Metabolic Health.
Medical disclaimer: This content is provided for general educational and informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition, and it does not create a physician-patient relationship. Every patient's medical history, health status, and treatment needs are different. Always consult your own physician or qualified healthcare provider before starting, stopping, or changing any medication or treatment, and before making any decisions based on information found here. If you are experiencing a medical emergency, call 911 or go to your nearest emergency room.